• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of immunologyLink to Publisher's site
Immunology. Sep 2010; 131(1): 9–17.
PMCID: PMC2966753

Autophagy and adaptive immunity

Abstract

Autophagy plays an important role in maintaining intracellular homeostasis by promoting the transit of cytoplasmic material, such as proteins, organelles and pathogens, for degradation within acidic organelles. Yet, in immune cells, autophagy pathways serve an additional role in facilitating intracellular surveillance for pathogens and changes in self. Autophagy pathways can modulate key steps in the development of innate and adaptive immunity. In terms of adaptive immunity, autophagy regulates the development and survival of lymphocytes as well as the modulation of antigen processing and presentation. Specialized forms of autophagy may be induced by some viral pathogens, providing a novel route for major histocompatibility complex (MHC) class I antigen presentation and enhanced CD8+ T-cell responses. Autophagy induction in target cells also increases their potential to serve as immunogens for dendritic cell cross-presentation to CD8+ T cells. The requirement for autophagy in MHC class II presentation of cytoplasmic and nuclear antigens is well established, yet recent studies also point to a critical role for autophagy in modulating CD4+ T-cell responses to phagocytosed pathogens. Autophagy pathways can also modulate the selection and survival of some CD4+ T cells in the thymus. However, much still remains to be learned mechanistically with respect to how autophagy and autophagy-linked genes regulate pathogen recognition and antigen presentation, as well as the development and survival of immune cells.

Keywords: antigen presentation, autophagy, histocompatibility antigens, T cells

Introduction

Autophagy has been defined as an ‘auto-digestive’ process that promotes the delivery of intracellular components from the cytoplasm to lysosomal or vacuolar compartments for terminal degradation and recycling. Thus, in many cells, autophagy functions in the removal of aggregated and misfolded proteins, in the turnover of senescent or damaged organelles, in cellular remodelling and in regenerating molecular building blocks during conditions of stress. Autophagy is also now widely recognized as playing an important role in modulating several pathways involved in immune recognition and responsiveness. Cells of the immune system exploit autophagy as a means to detect invading pathogens or changes in the status of self, and to initiate innate and/or adaptive immune responses. This review will focus on the importance of autophagic processes within antigen-presenting cells (APC) and how these pathways facilitate immune surveillance to influence T-cell responses. Autophagy-related genes may also function in processes that are only indirectly linked to degradation, and the potential importance of these findings in terms of host immunity is briefly discussed.

Pathways for autophagy

Bulk and selective transport via autophagy

In eukaryotic cells, multiple constitutive and inducible pathways for autophagy promote cargo delivery from the cytoplasm to vacuolar organelles for degradation. Two of these routes – microautophagy and macroautophagy – were initially described as bulk processes that indiscriminately capture cytoplasmic components, including proteins, ribosomes and organelles, for digestion in acidic vacuolar compartments such as lysosomes.1 Microautophagy has been extensively studied in yeast but few reports have been published addressing the significance of this pathway in mammalian cells. During microautophagy, lysosomal membrane invaginations directly engulf cytoplasmic components, including organelles such as nuclei, peroxisomes and mitochondria, for digestion. Notably, while some pharmacological agents have been used to distinguish microautophagy from macroautophagy, both pathways appear to utilize a conserved family of autophagy-related (Atg) proteins.2,3

Macroautophagy is constitutively active at low levels in many mammalian cells, promoting the degradation of long-lived proteins and organelles.1 During cellular-nutrient or growth-factor deprivation, bulk macroautophagy is rapidly induced to salvage amino acids. While macroautophagy was classically defined as indiscriminate, there may be some selectivity in directing molecules for digestion via this pathway. Degradation of polyubiquitinated protein aggregates by macroautophagy is dependent on their ability to bind a conserved adaptor protein, p62/SQSTM1.3 This may facilitate the clearance of misfolded protein aggregates, which are unable to access the proteasome for conventional cytoplasmic degradation. p62/SQSTM1 also binds light chain-3 (LC3), a homologue of yeast Atg8 that is important in macroautophagy.4 Antigenic epitopes linked to LC3 are digested by macroautophagy and transported to major histocompatibility complex (MHC) class II+ compartments within APC for presentation to CD4+ T cells.5 Specialized forms of macroautophagy have also evolved to promote the selective encapsulation of cytoplasmic microorganisms (xenophagy), the turnover of mitochondria (mitophagy), the clearance of peroxisomes (pexophagy) and nuclear degradation (nucleophagy). The steps imparting specificity to each of these pathways still remain poorly defined. p62/SQSTM1 has been implicated in conferring specificity during xenophagy, as autophagic capture of some cytoplasmic bacteria was linked to this adaptor protein and polyubiquitinated bacterial proteins.6 In xenophagy, activation of autophagy pathways in response to innate signalling may be important in selectively promoting pathogen sequestration or destruction. Interferon-γ (IFN-γ) treatment of macrophages stimulates autophagy and the destruction of phagocytosed pathogens, which is dependent on the expression of Irgm1, an immunity-related guanosine triphosphatase that regulates autophagy.7 Surprisingly, Irmg1 also functions in promoting T-cell survival following stimulation with IFN-γ, probably by preventing autophagy-induced T-cell death.8 Polymorphisms at the immunity-related GTPase family, M loci in humans are linked to susceptibility to Crohn's disease.9 The selective autophagy of mitochondria (mitophagy) is mediated by Ulk1 and multiple conserved Atg proteins, including Atg5 and Atg7.3,10 In mice, deletion of the autophagy genes Atg7 or Atg5 results in severe developmental consequences and impairs the generation and survival of B lymphocytes and mature T lymphocytes.1113 Analysis of T lymphocytes from Atg7-deficient mice revealed an increased amount of cellular reactive oxygen species, which was attributed to impaired mitophagy.14 It is therefore important to recognize that autophagy pathways and Atg proteins play multiple, and sometimes counterintuitive, roles in immune cells.

The ins and outs of macroautophagy

In immune cells, macroautophagy can be up-regulated by the activation of innate immune receptors, including toll-like receptor (TLR) ligation, nucleotide-binding oligomerization domain protein (NOD)1 and NOD2 engagement, and receptors for cytokines such as IFN-γ.7,8,11,1518 Yet, mechanistically how these signals promote autophagy is not well defined. By contrast, the initiation of macroautophagy in response to nutrient/growth factor depletion has been studied in detail. Depletion of cellular growth factors disrupts signalling through growth factor receptors and prevents the activation of a class I phosphatidylinositol-3 phosphatase (PI3P) kinase, which blocks the activation of mammalian target of rapamycin (mTOR).19 This failure to activate mTOR induces macroautophagy, a condition that is mimicked by treating cells with rapamycin. Macroautophagy is initiated in the cytoplasm by the formation of a crescent-shaped isolation membrane (IM) (Fig. 1). The class III PI3P kinase, Vps34, binds to Beclin 1, Vps15 and other cofactors to promote formation of the IM. This kinase complex is sensitive to 3-methyladenine and wortmannin, agents used to inhibit macroautophagy in cells. Yet, Vsp34 is not a perfect target for selectively disrupting autophagy because this kinase also associates with endosomes and phagosomes, regulating the fusion and transit of molecules between these organelles.19 Confirming the inhibition of macroautophagy using gene targeting, as well as pharmacological agents, is therefore important.11 The IM enlarges to capture and enclose its cytoplasmic cargo in a double membrane vesicle known as an autophagosome. This requires two protein-conjugation systems: the first consisting of Atg12-Atg5-Atg16L; and the second a complex to promote LC3 lipidation. Atg4, Atg7 and Atg3 promote cytoplasmic LC3-I processing and phosphatidylethanolamine conjugation, giving rise to LC3-II, which associates with the membranes of autophagosomes.

Figure 1
Macroautophagy modulates the degradation of long-lived proteins and organelles. Macroautophagy is initiated in the cytoplasm by the formation of an isolation membrane that engulfs macromolecules and organelles to yield a double-membrane vesicle known ...

Autophagosomes can fuse with early endosomes, multivesicular bodies, or late endosomes, giving rise to organelles known as amphisomes that subsequently fuse with lysosomes to form the terminal digestive compartment known as an autolysosome.19 During these fusion processes, proteases and lipases from endosomes and lysosomes are delivered into these autophagic vesicles to promote digestion of the contents, along with the transfer of proteins mediating endosome/lysosome fusion. However, in several cases, molecules captured from the cytoplasm into autophagosomes appear to reach TLR or MHC class II molecules within endosomes and lysosomes to promote innate or adaptive immunity.5,11,15 This would imply the transit of molecules from autophagosomes or amphisomes back into the endocytic network. Indeed, such transit for membrane-associated proteins was detected by live cell imaging.20 Stable autophagosome and lysosome fusion was observed approximately one-third of the time in cells, while, more frequently, these organelles docked, transferred their contents and then separated in a process dubbed ‘kiss and run fusion’. This may also explain reports of the co-localization of LC3 with class II molecules, the MHC encoded peptide editor (DM) and proteins resident in mature endosomes and phagosomes.5,18 The fusion of autophagosomes/amphisomes with phagosomes has yet to be documented, and much remains to be established in terms of defining how autophagy and Atg proteins promote phagosome maturation.16,2123

To ascertain a requirement for macroautophagy in immunological processes, investigators have frequently disrupted the expression of proteins linked to this pathway, including Beclin1, Atg12, Atg5, Atg7 or Atg16L1.11 However, caution is necessary as molecules such as Atg5 function in protein transport, separately from conventional macroautophagy and macromolecular degradation.11,22 Thus, the use of multiple complementary approaches to demonstrate a role for autophagy in immunology pathways is highly recommended. These include testing the effects of targeted disruption of several autophagy-linked or Atg proteins, biochemical assays to track the autophagy-linked conversion of LC3-I to LC3-II, morphological detection of double-membrane autophagosomes, or pharmacological disruption of macroautophagy.24,25 The detection of LC3 or fluorescent-tagged LC3 proteins bound to intracellular vesicles has been used as a measure of autophagosome formation; however, such results must be interpreted with considerable care as LC3 molecules function in membrane expansion and associate with other cellular structures, including RNA virus-replication complexes, the endoplasmic reticulum (ER), phagosomes, protein aggregates and lipid vacuoles.11,1621,2628 A recent report also documented the formation of autophagic vesicles in cells lacking both Atg5 and Atg7.29

Chaperone-mediated autophagy

Chaperone-mediated autophagy (CMA) is a highly selective pathway promoting protein delivery from the cytoplasm to endosomes and lysosomes.30 While constitutively active in many mammalian cells, this pathway is significantly up-regulated following prolonged cell duress as a result of nutrient depletion, upon oxidative or chemically induced stress and in response to protein misfolding. Macroautophagy and CMA are linked via their sequential induction in response to starvation. Macroautophagy is rapidly induced upon serum starvation but decreases after 24 hr, while cellular levels of CMA increase as macroautophagy subsides. Disruption of cellular Atg proteins that block macroautophagy results in increased protein transport and degradation via CMA.30 CMA is dependent upon a molecular chaperone complex composed of several heat shock proteins, including constitutively expressed heat shock 70-kDa protein (hsc70) and lysosome-associated membrane protein 2A (LAMP2A).31 Cytoplasmic proteins and peptides bearing a pentapeptide motif loosely homologous to the sequence KFERQ, associate with hsc70 and are delivered to a membrane translocation complex containing LAMP2A (Fig. 2). It is unclear whether additional molecular signals target proteins for CMA. CMA is ATP-dependent, and cytoplasmic hsc70 probably serves to select and promote the unfolding of substrates for translocation. hsc70 resident in endosomes and lysosomes is also required for translocation, yet whether this chaperone influences the processing of the transported proteins and peptides within these organelles is unknown. hsp90 in the cytoplasm also modulates CMA, although the precise role of this heat shock protein in substrate selection versus translocation is unclear. CMA diminishes with aging, and prolonged life span in rodents was observed with inducible expression of LAMP2A in the liver.32 In terms of innate immunity, mice lacking both LAMP2A and the highly homologous protein, LAMP2B, display reduced neutrophil phagosome maturation, probably as a result of defects in late endosome or lysosome fusion with phagosomes.33 As discussed next, both CMA and macroautophagy play important roles in modulating antigen (Ag) presentation.

Figure 2
Chaperone-mediated autophagy (CMA) is a regulated pathway that promotes protein delivery from the cytoplasm to endosomal compartments. In the cytoplasm, heat shock proteins, such as hsc70 and hsp90, selectively bind proteins or antigens (Ags) via the ...

Autophagy and Ag presentation

MHC class I-restricted Ag presentation and autophagy

CD8+ T cells recognize antigenic peptides in the context of MHC class I molecules expressed on the surface of nucleated cells. Epitopes from cytoplasmic and nuclear Ags, including viral proteins, endogenous tumour Ags and self-Ags, access class I molecules for presentation via a conventional pathway that is dependent upon the proteasome and a transporter for antigenic peptides (TAP).34,35 In the cytoplasm of cells, Ags are processed by the proteasome, with the resulting peptides translocating into the ER via TAP. In the ER these peptides may be further processed or directly bind newly synthesized MHC class I complexes with the aid of chaperone proteins. Peptide-loaded MHC class I complexes transit to the Golgi and gain entry into secretory vesicles for delivery to the cell surface. Using this pathway, MHC class I molecules access peptides from the cytoplasm and nucleus as a means to detect infection or cell transformation.

In dendritic cells and macrophages, an alternate path, termed cross-presentation, facilitates MHC class I presentation of epitopes from exogenous Ags and phagocytosed material. Cross-presentation is critical in promoting CD8+ T-cell responses to lipid-encapsulated Ags, tumour cells and bacteria.36,37 There are multiple pathways that promote Ag cross-presentation via MHC class I molecules, with the majority of these routes involving Ag capture by phagocytosis. Both TAP-dependent and TAP-independent routes for cross-presentation have been reported, as well as peptide loading by MHC class I molecules in the ER or phagosome before the egress of these resulting MHC class I–peptide complexes to the cell surface.

Evidence that autophagy directly influences the conventional pathway for MHC class I presentation is very limited, yet studies do suggest that the induction of autophagy may play a role in alternate pathways for MHC class I presentation. Inhibition of macroautophagy in APC by disrupting Atg12 or Atg5 expression, or by using pharmacological agents, failed to perturb MHC class I presentation of multiple endogenous and exogenous protein Ags.23,38,39,40 Conjugation of LC3 to a viral epitope similarly did not alter MHC class I presentation of this epitope.5 Yet, inhibition of macroautophagy in IFN-γ-treated B16 murine melanoma cells diminished MHC class I protein surface expression and tumour cell cytolysis by CD8+ T lymphocytes.41 MHC class I presentation by these IFN-γ-treated tumours was proteasome-dependent, suggesting a possible connection between autophagy and the conventional pathway for MHC class I presentation. Herpes simplex virus (HSV) infection of macrophages induces a novel autophagy pathway modulating MHC class I presentation. Initially, viral capsid Ag presentation in infected macrophages proceeds via the conventional MHC class I pathway.42 During the late stages of infection, viral capsid presentation is dependent upon Ag processing in acidic organelles as well as Atg5 expression. These HSV-infected cells contain LC3+ double-membrane vesicles that are closely associated with the nuclear envelope, consistent with virus induction of a novel form of xenophagy. HSV-1 encodes the ICP34.5 protein, which is known to inhibit classical macroautophagy, and in macrophages infected with an ICP34.5-deficient virus the accumulation of autophagosomes containing LC3 and the capsid Ag is detected. These studies suggest a potential role for some forms of autophagy in modulating MHC class I presentation by some tumours or virus-infected cells.

A small number of studies have examined the in vivo requirements for autophagy in MHC class I cross-presentation, and intriguing results were obtained. Selective deletion of Atg5 in dendritic cells did not alter the cross-presentation of phagocytosed Ags by MHC class I, as demonstrated using Ag-coated splenocytes.23 Yet, induction of autophagy in target cells did promote their cross-presentation to Ag-specific CD8+ T cells. CD8+ T-cell responses were enhanced using dendritic cells that had phagocytosed tumour cells treated with rapamycin or starvation to induce autophagy.43 Immunization of mice with purified autophagosomes from these tumour cells similarly promoted the activation of tumour-specific T cells. Using a related approach, in vivo immunization of mice with virus-infected ultraviolet (UV)-irradiated target cells, which were undergoing autophagy before cell death, also proved superior for inducing viral Ag cross-presentation to CD8+ T cells.44 This effect was dependent upon target-cell Atg5 expression, suggesting a requirement for target-cell autophagy induction. Dendritic cell production of type I IFNs in response to these virus-infected target cells was proposed as one possible explanation for this enhancement of CD8+ T-cell responses in vivo. Further mechanistic studies are needed to define how autophagic cells and autophagosomes serve as targets for MHC class I cross-presentation and to identify potential applications of these approaches for vaccine development.

MHC class II-restricted Ag presentation and autophagy

CD4+ T cells recognize antigenic peptides bound to MHC class II molecules expressed on APC and thymic epithelial cells (TEC). MHC class II protein expression can also be induced on non-professional APC and tumour cells following exposure to cytokines, TLR ligands and other activators of innate signalling pathways. Traditionally, MHC class II molecules were viewed as promoting CD4+ T-cell responses to extracellular pathogens and protein Ags, as well as inactivated viral vaccines. Yet, studies of human T-cell responses also suggested a role for MHC class II molecules in promoting immunity to infectious viruses and tumour Ags.4547 Sequencing of MHC class II ligands from a variety of APC revealed predominantly self-Ags found either on the cell surface or within the endosomal network.48,49 Yet, 10–30% of the ligands identified after release from MHC class II molecules are derived from cytoplasmic or nuclear Ags, suggesting that alternate pathways, such as autophagy, may deliver ligands to MHC class II molecules.48,50,51

MHC class II α and β subunits assemble in the ER with a conserved chaperone, the invariant chain (Ii), and transit to endosomal compartments. Within acidic endosomes, Ii is proteolytically cleaved, releasing peptide-receptive MHC class II αβ complexes. The binding of antigenic peptides to these MHC class II proteins is modulated by the editing molecules DM and peptide editor. MHC class II complexes travel through early endosomes, multivesicular bodies or mature endosomes (termed MIIC), lysosomes and phagosomes to acquire peptides before transit to the cell surface for display to CD4+ T cells.37,52 Ligand binding to MHC class II complexes at the cell surface is also observed, probably as a result of peptide exchange. Ags, including self- and foreign proteins, continuously traffick into the endosomal network for processing by cellular cathepsins and reductases. Remarkably, exposure of APC to cytokines such as IFN-γ and TLR ligands regulates autophagy pathways as well as cellular endocytosis.11,15,52,5356 The physical intersection of autophagy pathways with endosomes and lysosomes is critical in promoting cytoplasmic and nuclear Ag processing and presentation by MHC class II molecules (Figs 1 and and22).

A wide variety of short- and long-lived cytoplasmic and nuclear Ags, including viral, tumour, self- and ectopically expressed bacterial proteins, are presented by MHC class II molecules on APC and tumours, probably via several distinct autophagy pathways.57,58 Presentation of these Ags is typically sensitive to choloroquine or lysomotrophic amines, as these agents block the acidification of endosomal compartments through which MHC class II molecules transit. Remarkably, MHC class II presentation of some cytoplasmic Ags is dependent upon proteolysis by the proteasome or calpains,5961 while the processing of other nuclear and cytoplasmic Ags is mediated by cathepsin proteases in acidic compartments.38,39,5962 In contrast to MHC class I proteins, TAP is not required for MHC class II presentation of cytoplasmic or nuclear Ags.60,63,64 While cytoplasmic and nuclear Ags display some heterogeneity in their processing, these endogenous Ags also appear to access distinct pathways for autophagy. Exposure of APC to 3-methyladenine failed to perturb MHC class II presentation of a number of some cytoplasmic Ags, suggesting a role for pathways other than macroautophagy.60,61 Yet, for several nuclear and cytoplasmic Ags, 3-methyladenine was a potent inhibitor of MHC class II presentation (Fig. 1).5,38,39,61 Disrupting Atg12 or Atg7 expression via RNA interference (RNAi) also confirmed a requirement for macroautophagy in the presentation of two distinct nuclear Ags.5,38,40,65 MHC class II presentation of influenza matrix protein is enhanced by conjugation to LC3 before expression in APC.5 Whether nuclear localization favours Ag processing via macroautophagy, remains controversial. MHC class II presentation of a bacterial Ag via macroautophagy was found to be equally efficient regardless of whether this protein was ectopically expressed in the cytoplasm or in the nucleus of renal tumour cells.65 By contrast, MHC class II presentation of the viral Epstein Barr virus nuclear Ag 1 (EBNA1) by macroautophagy was enhanced upon deletion of its nuclear targeting sequence.40 Notably, macroautophagy is not involved in the presentation of epitopes from two other viral nuclear Ags – EBNA2 and EBNA3C – which rely on cross-presentation and processing via the conventional MHC class II pathway.66 Several cytoplasmic Ags access the selective autophagy pathway of CMA for MHC class II presentation (Fig. 2).63 Peptides from the cytoplasmic Ags glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and aspartate aminotransferase are frequently detected bound to MHC class II molecules, with the transit of both these Ags from the cytoplasm to lysosomes occurring via CMA.30,50,58 We showed previously that MHC class II presentation of cytoplasmic GAD65, a key diabetes autoantigen, is dependent upon CMA by manipulating the expression of LAMP2A and hsc70 in human B lymphoblasts.63 A recent study also demonstrated that both α and β isoforms of hsp90 are required for MHC class II presentation of cytoplasmic GAD Ag.67 Misfolded proteins in the ER are frequently translocated to the cytoplasm for proteolysis, and MHC class II presentation of one of these Ags was also dependent on CMA.63 Together these studies suggest that several autophagy pathways, which intersect the endosomal network, facilitate MHC class II presentation of cytoplasmic and nuclear Ags.

MHC class II presentation, autophagy and innate signalling

Several studies point to a role for autophagy or Atg proteins in promoting MHC class II presentation following innate signalling and phagocytosis (Fig. 3). Much like TLR ligands, muramyldipeptides can activate an innate signalling cascade mediated by NOD2, which induces autophagy and mobilizes the transit of intracellular MHC class II to the surface of dendritic cells.18 NOD2 activation also results in co-localization of the MHC class II editor, DM, with LC3 in intracellular vesicles. Disrupting dendritic cell expression of Atg5, Atg7 or Atg16L1 impairs the transit of MHC class II to the cell surface, DM co-localization with LC3 and MHC class II presentation of a bacterially delivered Ag in response to muramyldipeptides. Notably, genetic studies in humans have linked variants of NOD2 and ATG16L1 with susceptibility to Crohn's disease. Using dendritic cells from individuals expressing these genetic variants of NOD2 or ATG16L, muramyldipeptide treatment failed to induce cellular LC3+ vesicle accumulation, MHC class II transit to the cell surface and MHC class II presentation of bacterial Ags. Together these studies suggest roles for autophagy and Atg proteins in modulating innate immune responses to NOD2 ligands, as well as promoting the presentation of a phagocytosed bacterial Ag.

Figure 3
Autophagy, Atg proteins and pathogen phagocytosis. During phagocytosis, extracellular pathogens, such as bacteria, are internalized into phagosomes which fuse with endosomes and lysosomes to form phagolysosomes to promote pathogen degradation. Endosomes ...

Studies of HSV also suggest a connection among innate signalling, Atg proteins and Ag cross-presentation. HSV infection triggers innate signalling via TLRs, as well as the induction of adaptive CD4+ and CD8+ T-cell responses. In vivo activation of virus-specific CD4+ T cells was significantly impaired upon HSV infection of mice with Atg5-deficient dendritic cells.23 HSV-infected dendritic cells are unable to directly prime CD4+ T cells, leading this team of investigators to speculate that Atg5 expression in dendritic cells may modulate Ag cross-presentation. Indeed, MHC class II cross-presentation of phagocytosed Ags is significantly reduced in Atg5-deficient dendritic cells, but this is only observed in the presence of lipopolysaccharide (LPS). In the absence of TLR ligands, MHC class II cross-presentation of phagocytosed Ags was independent of Atg5 expression. Dendritic cells lacking Atg5 expression also displayed defects in MHC class II presentation of soluble protein Ags. Surprisingly in this model system, the induction of classical macroautophagy by dendritic cell starvation or treatment with rapamycin reduced MHC class II presentation of phagocytosed Ags. These studies reveal a role for Atg5 in MHC class II Ag presentation which is dependent on TLR activation but probably distinct from classical macroautophagy.

By contrast, the induction of autophagy using rapamycin or starvation enhanced MHC class II presentation of a secreted mycobacterial Ag following the phagocytosis of bacille Calmette–Guérin (BCG) by macrophages and dendritic cells.68 The induction of macroautophagy in these APC results in the enhanced delivery of lysosomal cathepsins and LC3 to mycobacteria-positive phagosomes. A secreted mycobacterial Ag (Ag85B) appears to localize in LC3+ autophagosomes, suggesting perhaps Ag release from phagosomes and recapture in autophagosomes. In vivo the immunization of mice with rapamycin-treated dendritic cells infected with mycobacteria increases the priming of IFN-γ-positive mycobacteria-specific CD4+ T cells. Whether these observations are specific for mycobacteria or are more broadly applicable, remains to be tested. These studies also suggest a role for classical macroautophagy in capturing intracellular Ags released from pathogens for MHC class II presentation. Yet, the recruitment or activation of Atg proteins may also play a critical role here in promoting phagosome maturation and pathogen killing. Much remains to be established in terms of understanding this latter process, as well as the multiple functions of Atg proteins in immune cells.

Autophagy and thymic selection

Developing T lymphocytes in the thymus interact with TEC, including cortical cells (cTEC), which promote positive selection, and medullary cells (mTEC), which function in negative selection to delete autoreactive T cells. In contrast to professional APC, TEC are inefficient at capturing and internalizing Ags by endocytosis.69 This has given rise to suggestions that TEC may rely heavily on intracellular pathways, such as autophagy, to acquire epitopes from endogenous or intracellular Ags for presentation in the context of MHC proteins. Analysis of thymus tissue from mice expressing a green fluorescent protein-conjugated LC3 (GFP–LC3) transgene expressed under the control of the actin promoter, revealed constitutive activation of macroautophagy in TEC, in contrast to tissues such as skeletal muscle.70 Nearly 70% of cTEC in murine thymic tissue sections contain GFP–LC3+ autophagosomes, compared with < 1% of dendritic cells and mTEC.71 A recent study also confirmed the detection of LC3-II in both cTEC and mTEC, along with the co-localization of MHC class II in vesicles with LC3 in immortalized TEC lines treated with IFN-γ.72 To test if macroautophagy in TEC influences T-cell selection, thymi from embryonic Atg5-deficient or wild-type mice were engrafted into adult wild-type mice or T-cell-receptor (TCR) transgenic mice.71 The cellular organization of thymi from Atg5-deficient mice is similar to that in wild-type animals, while TEC from these mice display normal levels of MHC class I expression and slightly reduced levels of MHC class II expression. Remarkably, positive selection of some, but not all, CD4+ TCR transgenic cell lines is impacted by the loss of thymic Atg5. Depending on the TCR transgenic line tested, no change, an increase, or a decrease, in the generation of single positive transgenic T cells is observed in animals lacking thymic Atg5. By contrast, no change in the selection of CD8+ T cells is observed with the deletion of Atg5 in the thymus. These studies are provocative in suggesting that Atg5, and potentially macroautophagy, can regulate the positive selection of T cells. Yet, neonatal lethality is observed in Atg5-deficient animals, as well as defects in T-cell development and survival.11 Further studies are needed to ensure that the loss of Atg5 in TEC selectively perturbs only macroautophagy to influence T-cell selection, especially in light of studies suggesting Atg5 regulation in multiple intracellular processes.1113,22,23

Concluding remarks

Immune cells, and in particular APC, exploit multiple intracellular pathways, including secretion, endocytosis, phagocytosis and autophagy, to survey the host and to modulate the activation of innate and adaptive responses. Evidence now suggests that in many cases CD4+ T-cell responses to pathogens are dependent on cellular autophagy pathways. Yet, much still remains to be ascertained to determine whether these observations are linked to a requirement for classical degradative autophagy, or reflect novel roles for autophagy-related proteins in innate signalling or in trafficking regulatory proteins to organelles such as phagosomes. Further studies are also required to define the role of autophagy in modulating CD8+ T-cell-mediated immunity, and in particular why phagosome maturation linked to autophagy enhances MHC class II, but not MHC class I, cross-presentation. The potential that autophagy induction in target cells may be useful in the development of vaccines that activate both CD4+ and CD8+ T cells is intriguing, particularly in light of the need for novel protocols for inducing protective immunity to tumours as well as emerging infectious diseases.

Acknowledgments

Grants from the National Institutes of Health and NIAID provide support to J.S.B. and V.L.C. for their work on autophagy and viral pathogens.

Disclosures

The authors have no financial conflicts of interest.

References

1. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069–75. [PMC free article] [PubMed]
2. Kunz JB, Schwarz H, Mayer A. Determination of four sequential stages during microautophagy in vitro. J Biol Chem. 2004;279:9987–96. [PubMed]
3. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol. 2009;335:1–32. [PMC free article] [PubMed]
4. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282:24131–45. [PubMed]
5. Schmid D, Pypaert M, Münz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity. 2007;26:79–92. [PMC free article] [PubMed]
6. Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, Brumell JH. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. J Immunol. 2009;183:5909–16. [PubMed]
7. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science. 2006;313:1438–41. [PubMed]
8. Feng CG, Zheng L, Jankovic D, et al. The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell death. Nat Immunol. 2008;9:1279–87. [PMC free article] [PubMed]
9. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830–2. [PMC free article] [PubMed]
10. Kundu M, Lindsten T, Yang CY, et al. Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. Blood. 2008;112:1493–502. [PMC free article] [PubMed]
11. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol. 2009;10:461–70. [PMC free article] [PubMed]
12. Pua HH, Dzhagalov I, Chuck M, Mizushima N, He YW. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J Exp Med. 2007;204:25–31. [PMC free article] [PubMed]
13. Miller BC, Zhao Z, Stephenson LM, et al. The autophagy gene ATG5 plays an essential role in B lymphocyte development. Autophagy. 2008;4:309–14. [PubMed]
14. Pua HH, Guo J, Komatsu M, He YW. Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J Immunol. 2009;182:4046–55. [PubMed]
15. Tal MC, Iwasaki A. Autophagy and innate recognition systems. Curr Top Microbiol Immunol. 2009;335:107–21. [PubMed]
16. Sanjuan MA, Dillon CP, Tait SW, et al. Toll-like receptor signaling in macrophages links the autophagy pathway to phagocytosis. Nature. 2007;450:1253–7. [PubMed]
17. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010;11:55–62. [PubMed]
18. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90–7. [PubMed]
19. Simonsen A, Tooze SA. Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. J Cell Biol. 2009;186:773–82. [PMC free article] [PubMed]
20. Jahreiss L, Menzies FM, Rubinsztein DC. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic. 2008;9:574–87. [PMC free article] [PubMed]
21. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004;119:753–66. [PubMed]
22. Zhao Z, Fux B, Goodwin M, et al. Autophagosome-independent essential function for the autophagy protein Atg5 in cellular immunity to intracellular pathogens. Cell Host Microbe. 2008;4:458–69. [PMC free article] [PubMed]
23. Lee HK, Mattei LM, Steinberg BE, et al. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity. 2010;32:227–39. [PMC free article] [PubMed]
24. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140:313–26. [PMC free article] [PubMed]
25. Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151–75. [PMC free article] [PubMed]
26. Korkhov VM. GFP-LC3 labels organized smooth endoplasmic reticulum membranes independently of autophagy. J Cell Biochem. 2009;107:86–95. [PMC free article] [PubMed]
27. Kuma A, Matsui M, Mizushima N. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy. 2007;3:323–8. [PubMed]
28. Shibata M, Yoshimura K, Tamura H, et al. LC3, a microtubule-associated protein1A/B light chain3, is involved in cytoplasmic lipid droplet formation. Biochem Biophys Res Commun. 2010;393:274–9. [PubMed]
29. Nishida Y, Arakawa S, Fujitani K, et al. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature. 2009;461:654–8. [PubMed]
30. Massey AC, Zhang C, Cuervo AM. Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol. 2006;73:205–35. [PubMed]
31. Kaushik S, Massey AC, Mizushima N, Cuervo AM. Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy. Mol Biol Cell. 2008;19:2179–92. [PMC free article] [PubMed]
32. Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med. 2008;14:959–65. [PMC free article] [PubMed]
33. Beertsen W, Willenborg M, Everts V, Zirogianni A, Podschun R, Schröder B, Eskelinen EL, Saftig P. Impaired phagosomal maturation in neutrophils leads to periodontitis in lysosomal-associated membrane protein-2 knockout mice. J Immunol. 2008;180:475–82. [PubMed]
34. Donaldson JG, Williams DB. Intracellular assembly and trafficking of MHC class I molecules. Traffic. 2009;10:1745–52. [PMC free article] [PubMed]
35. Raghavan M, Del Cid N, Rizvi SM, Peters LR. MHC class I assembly: out and about. Trends Immunol. 2008;29:436–43. [PMC free article] [PubMed]
36. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol. 2010;22:109–17. [PubMed]
37. Ramachandra L, Simmons D, Harding CV. MHC molecules and microbial antigen processing in phagosomes. Curr Opin Immunol. 2009;21:98–104. [PMC free article] [PubMed]
38. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol. 2003;33:1250–9. [PubMed]
39. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C. Endogenous MHC class II processing of a viral nuclear antigen afer autophagy. Science. 2005;307:593–6. [PubMed]
40. Leung CS, Haigh TA, Mackay LK, Rickinson AB, Taylor GS. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci USA. 2010;107:2165–70. [PMC free article] [PubMed]
41. Li B, Lei Z, Lichty BD, Li D, Zhang GM, Feng ZH, Wan Y, Huang B. Autophagy facilitates major histocompatibility complex class I expression induced by IFN-gamma in B16 melanoma cells. Cancer Immunol Immunother. 2009;59:313–21. [PubMed]
42. English L, Chemali M, Duron J, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol. 2009;10:480–7. [PMC free article] [PubMed]
43. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68:6889–95. [PMC free article] [PubMed]
44. Uhl M, Kepp O, Jusforgues-Saklani H, Vicencio JM, Kroemer G, Albert ML. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ. 2009;16:991–1005. [PubMed]
45. Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol. 1989;63:1756–62. [PMC free article] [PubMed]
46. Malnati MS, Ceman S, Weston M, DeMars R, Long EO. Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. J Immunol. 1993;151:6751–6. [PubMed]
47. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999;284:1351–4. [PubMed]
48. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993;178:27–47. [PMC free article] [PubMed]
49. Hunt DF, Michel H, Dickinson TA, et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science. 1992;256:1817–20. [PubMed]
50. Dongre AR, Kovats S, deRoos P, et al. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol. 2001;31:1485–94. [PubMed]
51. Dengjel J, Schoor O, Fischer R, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA. 2005;102:7922–7. [PMC free article] [PubMed]
52. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 2008;27:1–5. [PMC free article] [PubMed]
53. Krawczyk M, Leimgruber E, Seguín-Estévez Q, Dunand-Sauthier I, Barras E, Reith W. Expression of RAB4B, a protein governing endocytic recycling, is co-regulated with MHC class II genes. Nucleic Acids Res. 2007;35:595–605. [PMC free article] [PubMed]
54. Tsang AW, Oestergaard K, Myers JT, Swanson JA. Altered membrane trafficking in activated bone marrow-derived macrophages. J Leukoc Biol. 2000;68:487–94. [PubMed]
55. Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol. 2010;22:124–30. [PubMed]
56. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–89. [PubMed]
57. Zhou D, Blum JS. Presentation of cytosolic antigens via MHC class II molecules. Immunol Res. 2004;30:279–90. [PubMed]
58. Münz C. Enhancing immunity through autophagy. Annu Rev Immunol. 2009;27:423–49. [PubMed]
59. Lich JD, Elliott JF, Blum JS. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J Exp Med. 2000;191:1513–24. [PMC free article] [PubMed]
60. Mukherjee P, Dani A, Bhatia S, et al. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis. J Immunol. 2001;167:2632–41. [PubMed]
61. Dörfel D, Appel S, Grünebach F, Weck MM, Müller MR, Heine A, Brossart P. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood. 2005;105:3199–205. [PubMed]
62. Jaraquemada D, Marti M, Long EO. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med. 1990;172:947–54. [PMC free article] [PubMed]
63. Zhou D, Li P, Lin Y, Lott JM, Hislop AD, Canaday DH, Brutkiewicz RR, Blum JS. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity. 2005;22:571–81. [PubMed]
64. Dissanayake SK, Tuera N, Ostrand-Rosenberg S. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J Immunol. 2005;174:1811–9. [PubMed]
65. Riedel A, Nimmerjahn F, Burdach S, Behrends U, Bornkamm GW, Mautner J. Endogenous presentation of a nuclear antigen on MHC class II by autophagy in the absence of CRM1-mediated nuclear export. Eur J Immunol. 2008;2038:2090–5. [PubMed]
66. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol. 2006;177:3746–56. [PubMed]
67. Houlihan JL, Metzler JJ, Blum JS. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells. J Immunol. 2009;182:7451–8. [PMC free article] [PubMed]
68. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL, Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med. 2009;15:267–76. [PubMed]
69. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol. 2009;9:833–44. [PubMed]
70. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004;15:1101–11. [PMC free article] [PubMed]
71. Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature. 2008;455:396–400. [PubMed]
72. Kasai M, Tanida I, Ueno T, Kominami E, Seki S, Ikeda T, Mizuochi T. Autophagic compartments gain access to the MHC class II compartments in thymic epithelium. J Immunol. 2009;183:7278–85. [PubMed]

Articles from Immunology are provided here courtesy of British Society for Immunology
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...